|Bid||16.33 x 900|
|Ask||16.92 x 900|
|Day's range||16.00 - 16.62|
|52-week range||12.24 - 28.06|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.88|
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
SAN DIEGO, September 12, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The FDA has granted a priority review and assigned a PDUFA (Prescription Drug User Fee Act) action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.